File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment algorithms for mature T-cell and natural killer-cell neoplasms

TitleTreatment algorithms for mature T-cell and natural killer-cell neoplasms
Authors
Issue Date2011
PublisherFuture Medicine Ltd. The Journal's web site is located at http://www.futuremedicine.com/loi/fon
Citation
Future Oncology, 2011, v. 7 n. 9, p. 1101-1112 How to Cite?
AbstractMature T-cell and natural killer (NK)-cell lymphomas are rare neoplasms, differing geographically in frequencies. T-cell lymphomas are more common in Asia than in western countries, and NK-cell lymphomas occur almost exclusively in Asia and South America. The rarity of these lymphomas means that treatment algorithms of T-cell and NK-cell lymphomas have not been well established. Angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma and peripheral T-cell lymphoma, not otherwise specified, are the more commonly encountered T-cell lymphomas. Treatment with anthracycline-based regimens designed for aggressive B-cell lymphomas gives unsatisfactory results. Cutaneous T-cell lymphomas may remain indolent, but outcome is poor for advanced diseases. Novel therapies, including monoclonal antibodies, nucleoside analogs, histone deacetylase inhibitors and small molecules targeting cellular signaling pathways, are being explored alone or in combination with chemotherapy. High-dose chemotherapy with hematopoietic stem cell transplantation (HSCT) is recommended for high-risk cases. NK-cell lymphomas exhibit the multidrug resistance phenotype due to P-glycoprotein expression, so that anthracycline-based regimens are ineffective. Non-multidrug resistance-dependent regimens and L-asparaginase-based protocols have been shown to be highly active. Autologous HSCT is not routinely performed. The role of allogeneic HSCT is being examined.
Persistent Identifierhttp://hdl.handle.net/10722/163402
ISSN
2015 Impact Factor: 2.129
2015 SCImago Journal Rankings: 0.957
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTse, Een_US
dc.contributor.authorKwong, YLen_US
dc.date.accessioned2012-09-05T05:30:56Z-
dc.date.available2012-09-05T05:30:56Z-
dc.date.issued2011en_US
dc.identifier.citationFuture Oncology, 2011, v. 7 n. 9, p. 1101-1112en_US
dc.identifier.issn1479-6694en_US
dc.identifier.urihttp://hdl.handle.net/10722/163402-
dc.description.abstractMature T-cell and natural killer (NK)-cell lymphomas are rare neoplasms, differing geographically in frequencies. T-cell lymphomas are more common in Asia than in western countries, and NK-cell lymphomas occur almost exclusively in Asia and South America. The rarity of these lymphomas means that treatment algorithms of T-cell and NK-cell lymphomas have not been well established. Angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma and peripheral T-cell lymphoma, not otherwise specified, are the more commonly encountered T-cell lymphomas. Treatment with anthracycline-based regimens designed for aggressive B-cell lymphomas gives unsatisfactory results. Cutaneous T-cell lymphomas may remain indolent, but outcome is poor for advanced diseases. Novel therapies, including monoclonal antibodies, nucleoside analogs, histone deacetylase inhibitors and small molecules targeting cellular signaling pathways, are being explored alone or in combination with chemotherapy. High-dose chemotherapy with hematopoietic stem cell transplantation (HSCT) is recommended for high-risk cases. NK-cell lymphomas exhibit the multidrug resistance phenotype due to P-glycoprotein expression, so that anthracycline-based regimens are ineffective. Non-multidrug resistance-dependent regimens and L-asparaginase-based protocols have been shown to be highly active. Autologous HSCT is not routinely performed. The role of allogeneic HSCT is being examined.en_US
dc.languageengen_US
dc.publisherFuture Medicine Ltd. The Journal's web site is located at http://www.futuremedicine.com/loi/fonen_US
dc.relation.ispartofFuture Oncologyen_US
dc.subject.meshAlgorithmsen_US
dc.subject.meshAntineoplastic Agents - therapeutic useen_US
dc.subject.meshKiller Cells, Naturalen_US
dc.subject.meshLymphoma - diagnosis - pathology - therapyen_US
dc.subject.meshLymphoma, T-Cell - diagnosis - pathology - therapyen_US
dc.titleTreatment algorithms for mature T-cell and natural killer-cell neoplasmsen_US
dc.typeArticleen_US
dc.identifier.emailTse, E: ewctse@hku.hken_US
dc.identifier.emailKwong, YL: ylkwong@hku.hken_US
dc.identifier.authorityTse, E=rp00471en_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.2217/fon.11.84en_US
dc.identifier.pmid21919697-
dc.identifier.scopuseid_2-s2.0-80053039219en_US
dc.identifier.hkuros207902-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-80053039219&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume7en_US
dc.identifier.issue9en_US
dc.identifier.spage1101en_US
dc.identifier.epage1112en_US
dc.identifier.isiWOS:000296257600012-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US
dc.identifier.scopusauthoridTse, E=7005019454en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats